The fatal infectious complications experienced by both of our patients emphasize the importance of recovery of immune function following UCB transplantation. In the patients reported here, immune deficits may have been exacerbated by the previous transplantations or the second preparative regimen. The severity of infectious complications experienced by these patients suggests that additional treatments may be required to reduce the infection risk in similarly treated patients in the future. Finally, omission of the pre-UCB transplant preparative regimen or reducing its intensity could be considered, but might risk UCB engraftment. In spite of these immune complications, the re-establishment of neutrophil and platelet engraftment in both patients suggests that the 'rescue' use of UCB, as described here, could be explored further. The marked improvement in the survival of children treated for cancer has focused increased attention on the long-term sequellae associated with contemporary intensive therapies. Second malignancies have been reported in patients treated for variety of childhood cancers, and have been associated with alkylating agents, topoisomerase inhibitors and radiation. Genetic differences in drug metabolizing enzymes may explain some of the variability in drug response. 1 Thus, common genetic polymorphisms in drug metabolizing enzymes may result in impaired detoxification of chemotherapeutic agents, resulting in higher levels of genotoxic substrates that could contribute to increased DNA damage and subsequent development of second neoplasms.
Glutathione S-transferases (GST) are supergene family capable of detoxifying genotoxic electrophilic compounds by catalyzing their conjugation to glutathione. At least five of the human GST genes have functional polymorphisms. 2 The GSTM1 and GSTT1 polymorphisms are deletions, with homozygous variant patients producing no active protein. The GSTM1 gene is homozygously deleted in 50% of Caucasian individuals and GSTT1 in 20%.
3 GSTP1 gene is also polymorphic, with a codon 105 isoleucine-valine substitution (GSTP n 1B), resulting in altered catalytic activity and thermal stability of the enzyme. The GSTM1 and GSTT1 alleles have been associated with increased risk of development of a variety of solid tumors and leukemia. 4 The risk for cancer conferred to individuals who carry homozygous deletions in GSTM1 and GSTT1 appears to be small in magnitude; however, the magnitude of risk is larger when interactions with other carcinogenic factors such as smoking are considered. 4 Epipodophyllotoxins, anthracyclines and cyclophosphamide are also inactivated by these enzymes, play integral roles in the treatment of pediatric leukemias, and are also risk factors for the development of secondary leukemias.
We sought to evaluate the role that GST genotypes play in modifying the risk of secondary malignancies in children treated for acute leukemia. We compared the proportion of GSTM1, GSTT1 and GSTP n 1B genotypes in pediatric patients who developed secondary cancers after treatment of acute leukemia to a control group of pediatric patients who did not develop a secondary malignancy while treated on identical protocols. A total of 449 patients under 16 years of age were treated between 1 January 1961 and 12 October 2000 for acute leukemia and were registered in Cancer Registry of Slovenia. Of these, 16 patients developed second neoplasm 1.76-20.4 years after the diagnosis of leukemia (mean 9.3 years, s.d. 4.8 years). Patients with secondary leukemia were matched to two patients on diagnosis, age at diagnosis, gender and for the length of observation period. In all cases, initial leukemia therapy consisted of combined multiagent chemotherapy and cranial irradiation according to treatment protocols used at that time. DNA was extracted from archived bone marrow smears by using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendation for archived bone marrow. The deletions of GSTM1 and GSTT1 were detected using multiplex PCR as described by Chen et al. Exons 5 and 6 of GSTP1 gene were separately amplified and genotype with an RLFP digest. Primer sequences and PCR conditions are available from the corresponding author. Genotyping was randomly repeated in 10% of samples to check for the typing reliability. Table 1 summarized patient characteristics and genotypes.
Cases and controls were matched on gender, time of observation and age at the diagnosis. In both groups there was higher percentage of males. The most frequent second neoplasms were neoplasms of the central nervous system (CNS) in six cases, followed by non-Hodgkin's lymphoma (NHL) in three cases, Hodgkin's lymphoma (HD) and acute myeloblastic leukemia (AML) in two cases each. Osteosarcoma, fibrosarcoma and basal cell carcinoma were observed in one case each. GSTM1, GSTT1 and GSTP1 codon 105 genotype analyses were successfully performed in all 48 patients. Genotype prevalence in the entire study population were as follows: GSTM1 þ 52%, GSTM1 null 48%, GSTT1 þ 77%, GSTT1 null 23%, GSTP1 Table 2 presents the distribution of GSTM1, GSTT1, GSTP1 codon 105 genotypes and their association with the occurrence of second neoplasms in cases and controls. We separately analyzed the chemotherapy-related cases of secondary AML, NHL and HD.
Overall, we found no statistically significant difference in distribution of GST genotypes in patients with second neoplasms after childhood leukemia as compared with a matched control group of patients. Even after subdivision of cases to radiotherapy related (CNS tumors, osteosarcoma, soft-tissue sarcoma, skin cancer) and chemotherapy related (AML, NHL, HD), no statistically significant differences were found (Table 2) . Moreover, in our study population of children with acute leukemia the prevalence of the GSTM1 and GSTT1 null genotype was 48 and 23% respectively, which is comparable with the frequency observed in general population in Slovenia, where GSTM1 null genotype was found in 54% and GSTT1 null genotype in 24% Our study provides additional data suggesting that individual GST polymorphisms do not markedly modify the risk of secondary malignancies in children treated for ALL. Woo et al. 6 studied 302 children with acute lymphoblastic leukemia, among whom 57 developed treatment-related leukemia or myelodysplastic syndrome and found no association of GSTM1 or GSTT1 null genotypes with treatment-related malignancies. Crump et al 7 found a slightly higher prevalence of the GSTM1 and GSTT1 gene deletions among patients with secondary AML as compared to the patients with de novo AML or controls; however, this result was not statistically significant. Interestingly, Haase et al 8 reported that patients with breast carcinoma and inheritance of double null deletion of GSTM1 and GSTT1 may have an increased risk of a secondary therapy-induced hematologic neoplasm. Future studies, with adequate samples sizes, will be required to confirm the role of GST double deletions and secondary AML risk.
The small size of our study group and heterogeneity of the observed secondary neoplasms limits the power of this study to explore the relationship between particular secondary malignancies and GST genotype. Although our data does not support an association between GST genotype and occurrence of second neoplasms after the treatment of childhood acute leukemia, our results are consistent with those of other investigators. While single GST polymorphisms do not appear to be a major modifier of secondary leukemia risk, it is possible that investigation of polymorphisms in other genes involved in drug detoxification will enable development of genetic risk profiles for therapyrelated secondary malignancies. Tumor lysis syndrome commonly occurs in patients with acute leukemia and non-Hodgkin's lymphoma with a high tumor burden, even before any antineoplastic treatment is given. Severe complications like hyperkalemia and renal failure induced by uric acid and/or calcium phosphate crystals can arise. Prophylaxis and treatment standards for tumor lysis syndrome are adequate hydration, correction of electrolyte disturbances, neutralization of urine-pH and allopurinol. 1 Allopurinol blocks the conversion of hypoxanthine and xanthine to uric acid. Xanthine is less soluble than uric acid, even in alkaline urine (150 mg/l xanthine as compared to 2000 mg/l uric acid at pH 7). Therefore, xanthine nephropathy and xanthine stone formation can result. 2, 3 Recent studies have shown that rasburicase, a recombinant urate oxidase, is more effective in lowering urate levels as compared to allopurinol and is well tolerated. 1, 4, 5 The dose of rasburicase used in studies and recommended by the manufacturer for prevention of hyperuricemia is 0.2 mg/kg body weight for the first 5-7 days of chemotherapy. In patients treated with rasburicase, plasma urate levels dropped by 86% within 4 h following the first drug dose. 4 Costs of a 7-day rasburicase treatment with 0.2 mg/kg in adult patients (70 kg) amount to approximately h7100. As a reduction of plasma urate below the normal range (3.5-7 mg/dl) is not necessary to prevent uric acid nephropathy, we treated patients with lower doses of rasburicase to reduce treatment costs.
We report on the results of four patients (two with advanced lymphoma and two with acute leukemia) with tumor lysis syndrome and renal failure who were successfully treated with recombinant urate oxidase with a lower dose per day and/or
